• 16
  • Comment
  • Favorite

Apple, NIO, Grab, XPeng, Li Auto, WeWork And More: U.S. Stocks To Watch

Dow Jones2023-09-13

Stock futures slipped Wednesday ahead of U.S. consumer price index data. Economists forecast that CPI climbed at a 3.6% annual pace in August, up from the 3.2% pace recorded in July.

These stocks were poised to make moves Wednesday:

Apple $(AAPL)$ slid slightly, a day after declining 1.7% following the release of its new iPhone lineup. While some analysts had expected price increases across the Pro lineup, Apple only increased the starting price of its iPhone 15 Pro Max phone by $10.

U.S.-listed shares of BP $(BP)$ rose 2.4% in premarket trading after Chief Executive Bernard Looney resigned amid an investigation into new allegations of his personal relationships with colleagues. Looney had pushed for the oil giant's transition to clean energy.

American depositary receipts of NIO and Li Auto $(LI)$ declined over 2%, XPeng $(XPEV)$ was down over 3% after European Commission President Ursula von der Leyen said an anti-subsidy investigation would be launched into Chinese electric-vehicle makers.

Grab fell over 2% in premarket trading as Singapore-based ride-hailing company Ryde was seeking to list on the New York Stock Exchange (NYSE). The company intended to raise up to $17 million in an initial public offering (IPO), with no pricing terms disclosed.

Wework crashed over 8% in premarket trading after it rocketed 87% on heavy volume on Tuesday, and have more than doubled in two days. Before that, the company's 1-for-40 reverse stock split took effect at the market open on Sept. 5, which effectively multiplied the stock's price by 40.

Workhorse Group surged nearly 20% in premarket trading as it has received IRS approval as a qualified manufacturer for the Commercial Clean Vehicle Credit under the terms of the Internal Revenue Code.

Rocket Pharmaceuticals $(RCKT)$ jumped 17% after the pharmaceutical company said it reached alignment with the Food and Drug Administration regarding its global Phase 2 trial for treatment of Danon disease, a fatal genetic cardiac disease.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

empty
No comments yet
 
 
 
 

Most Discussed

 
 
 
 
 

7x24

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email:uservice@ttm.financial